Thursday, February 29, 2024
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



Cuba’s dengue vaccine candidate based on recombinant proteins

Havana, Mar 21 (Prensa Latina) Cuba´s vaccine candidate to treat dengue has a safe technological platform, as informed by the Center for Genetic Engineering and Biotechnology (CIGB).

“The vaccine candidate to fight dengue is based on recombinant proteins: a safe technological platform,” CIGB tweeted.

“We are currently assessing a tetravalent candidate, based on proteins of the four dengue viruses,” CIGB added.

Whether infection level by the dengue virus – that is, the viral load – is lowered, severity is avoided; even symptomatology.

“This is what we are betting on with the new vaccine candidate: that the disease is subclinical or with mild symptoms,” according to CIGB.

Obtaining the vaccine is a complex process, because dengue has four serotypes and it is necessary to immunize against each of them at the same time for the product to be effective.

A new system for rapid diagnosis of dengue should be available in 2023.

In statements to Granma newspaper, Eduardo Martínez, president of the Biotechnological and Pharmaceutical Industries Business Group, argued that such a system would make it possible to determine, upon the appearance of the first symptoms, whether it is dengue or a second infection.

According to Martínez, this will be useful to apply a differentiated treatment to patients and avoid death.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.